KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Non-Current Assets (2016 - 2025)

West Pharmaceutical Services' Non-Current Assets history spans 17 years, with the latest figure at $2.3 billion for Q3 2025.

  • For Q3 2025, Non-Current Assets rose 7.44% year-over-year to $2.3 billion; the TTM value through Sep 2025 reached $8.8 billion, up 11.18%, while the annual FY2024 figure was $2.1 billion, 11.21% up from the prior year.
  • Non-Current Assets for Q3 2025 was $2.3 billion at West Pharmaceutical Services, roughly flat from $2.3 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $2.3 billion in Q3 2025 and bottomed at $1.4 billion in Q1 2021.
  • The 5-year median for Non-Current Assets is $1.8 billion (2023), against an average of $1.8 billion.
  • The largest annual shift saw Non-Current Assets rose 2.52% in 2022 before it increased 19.19% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $1.6 billion in 2021, then increased by 7.98% to $1.7 billion in 2022, then rose by 11.54% to $1.9 billion in 2023, then rose by 11.21% to $2.1 billion in 2024, then increased by 8.42% to $2.3 billion in 2025.
  • Per Business Quant, the three most recent readings for WST's Non-Current Assets are $2.3 billion (Q3 2025), $2.3 billion (Q2 2025), and $2.2 billion (Q1 2025).